Protective role of imatinib in atherosclerosis.
Kadowaki
Takashi
T
Kubota
Naoto
N
D000818:Animals; D001057:Apolipoproteins E / Q000172:deficiency / Q000235:genetics; D001161:Arteriosclerosis / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D001549:Benzamides; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000201:enzymology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000201:enzymology; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D000068877:Imatinib Mesylate; D007333:Insulin Resistance; D024821:Metabolic Syndrome / Q000188:drug therapy* / Q000201:enzymology; D051379:Mice; D018345:Mice, Knockout; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use*; D010982:Platelet-Derived Growth Factor / Q000502:physiology; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use*; D017479:Receptors, Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors*; D012307:Risk Factors
D001057:Apolipoproteins E; D001549:Benzamides; D002316:Cardiotonic Agents; D004791:Enzyme Inhibitors; D010879:Piperazines; D010982:Platelet-Derived Growth Factor; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D017479:Receptors, Platelet-Derived Growth Factor